Atrys Health, S.A.
Atryu operates in the healthcare facilities and services sector, focusing on biotechnology, and generates revenue primarily through its operations in this field.
Business. ATRY.MC is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models and is headquartered in Madrid, Spain. It is primarily listed on the BME (Madrid) exchange under the ticker ATRY.MC. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ATRY.MC is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models and is headquartered in Madrid, Spain. It is primarily listed on the BME (Madrid) exchange under the ticker ATRY.MC. Specific details regarding operating segments and geographic revenue mix are not available.
Atryu's capital structure is characterized by a debt-to-equity ratio of 1.7, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.81, suggesting that it may face challenges in meeting its short-term obligations. The company's valuation snapshot reveals a negative return on equity of -0.6605 and a negative return on assets of -0.203, indicating poor profitability and asset utilization.
In terms of profitability, Atryu's operating income is negative at -41.744 million EUR, and its net income is also negative at -100.296 million EUR. These figures are below the industry median for profitability metrics, suggesting that the company is underperforming relative to its peers. The company's gross profit of 61.346 million EUR is a positive indicator, but it is not sufficient to offset the operating and net losses.
Atryu's revenue is concentrated in a single segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Europe. This concentration may expose the company to regional economic and regulatory risks.
The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. However, the negative operating and net income figures suggest that the company is not currently experiencing growth. The company's capital expenditure of -12.517 million EUR indicates a reduction in investment in long-term assets.
Atryu's risk assessment highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company's dilution potential is low, as there is no significant difference between basic and diluted shares outstanding.
Recent events and filings do not provide specific details on Atryu's operations or financial performance. The company's financial statements and analyst estimates suggest that it is facing financial challenges, with a mean price target of 4.83 EUR and a median price target of 5.00 EUR. The mean recommendation from analysts is 1.33, indicating a generally positive outlook, but the company's financial performance may not support this optimism.
- Atryu has a high debt-to-equity ratio of 1.7, indicating a significant reliance on debt financing.
- The company's profitability is poor, with a negative return on equity of -0.6605 and a negative return on assets of -0.203.
- Atryu's revenue is concentrated in a single segment, and its geographic exposure is primarily in Europe.
- The company's liquidity position is medium, with a current ratio of 0.81, suggesting potential challenges in meeting short-term obligations.
- Analysts have a generally positive outlook on Atryu, with a mean price target of 4.83 EUR and a mean recommendation of 1.33.
- margin_outlook_rationale: The company's gross profit margin is positive but insufficient to offset operating and net losses, indicating potential margin compression.
- rd_outlook_rationale: No specific information is provided on the company's research and development activities or their impact on future profitability.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,06 |
| Revenue | —no estimate | —no estimate | 177,0M EUR |
| Operating income | —no estimate | —no estimate | 11,7M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ATRY.MC Market data — financials · 2026-05-27
- Atrys Health SA Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Santiago de Torres SanahujaExecutive Chairman of the Board